- Haemonetics shares have been punished since April on the back of CSL Plasma's decision not to renew the use of PCS2 from June 2022.
- Shares immediately saw a gap-fill to the downside and have shown downward pressures since, however, fundamentally little has changed.
- Theoretically ~12% of HAE's top line remains unhedged going forward, but all clients have already adopted NexSys - currently under-reflected.
- Technical studies exhibit a downward pressure on shares, but the question remains on whether the fundamentals will follow.
- Here, we present all of the relevant moving parts in the investment debate, for the benefit of investors' own reasoning.
For further details see:
Haemonetics Corp: Contrarian Flavour With Recent Market Punishment